Identification

Name
Calcium Acetate
Accession Number
DB00258  (APRD00839)
Type
Small Molecule
Groups
Approved
Description

The chemical compound calcium acetate is the calcium salt of acetic acid. An older name is acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. [Wikipedia]

Structure
Thumb
Synonyms
  • Acetate OF lime
  • Brown acetate of lime
  • Ca(oac)2
  • calcium ethanoate
  • calcium(II) acetate
  • Gray acetate of lime
  • Lime acetate
  • Lime pyrolignite
External IDs
E-263 / FEMA NO. 2228 / INS NO.263 / INS-263
Product Ingredients
IngredientUNIICASInChI Key
Calcium acetate monohydrate7ZA48GIM5H5743-26-0XQKKWWCELHKGKB-UHFFFAOYSA-L
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium AcetateCapsule667 mg/1OralSandoz2012-03-14Not applicableUs
Calcium AcetateCapsule667 mg/1OralClinical Solutions Wholsesale2012-03-14Not applicableUs
Calcium AcetateCapsule667 mg/1OralSandoz2012-03-14Not applicableUs
Calcium AcetateCapsule667 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
PhosLoCapsule667 mg/1OralFresenius Medical Care North America2001-04-02Not applicableUs
PhosloCapsule667 mg/1OralPhysicians Total Care, Inc.2010-03-01Not applicableUs49230 0640 21 nlmimage10 c81c6413
PhosloCapsule667 mg/1OralCardinal Health2001-04-02Not applicableUs
Phoslo TabletsTablet667 mgOralFresenius Medical Care North America2006-02-222013-07-29Canada
PhoslyraSolution667 mg/5mLOralFresenius Medical Care North America2011-04-15Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium AcetateCapsule667 mg/1OralMc Kesson Contract Packaging2013-04-09Not applicableUs
Calcium AcetateCapsule667 mg/1OralWest Ward Pharmaceutical2008-02-26Not applicableUs
Calcium AcetateCapsule667 mg/1OralHeritage2015-07-07Not applicableUs
Calcium AcetateCapsule667 mg/1OralLotus Pharmaceutical Co., Ltd. Nantou Plant2016-09-012016-12-28Us
Calcium AcetateCapsule667 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Calcium AcetateCapsule667 mg/1OralCardinal Health2008-02-26Not applicableUs
Calcium AcetateCapsule667 mg/1OralAtlantic Biologicals Corps.2008-02-26Not applicableUs
Calcium AcetateCapsule667 mg/1OralAmerincan Health Packaging2012-08-27Not applicableUs
Calcium AcetateTablet667 mg/1OralZydus Pharmaceuticals Usa, Inc.2012-02-23Not applicableUs
Calcium AcetateCapsule667 mg/1OralAvera Mc Kennan Hospital2016-02-15Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Acetate Tab 667mgTablet667 mgOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1993-12-312002-07-31Canada
International/Other Brands
Teltozan
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Aluminum Acetate AstringentCalcium Acetate (839 mg/2030mg) + Aluminum sulfate (1191 mg/2030mg)Powder, for solutionTopicalTagi Pharma Incorporated2011-06-15Not applicableUs
AstringentCalcium acetate monohydrate (952 mg/2299mg) + Aluminum sulfate tetradecahydrate (1347 mg/2299mg)Powder, for solutionTopicalTAGI Pharma, Inc.2012-06-01Not applicableUs
DomeboroCalcium acetate monohydrate (952 mg/1) + Aluminum sulfate tetradecahydrate (1347 mg/1)Powder, for solutionTopicalMOBERG PHARMA NORTH AMERICA LLC2012-06-26Not applicableUs
Hyperlyte (multi-electrolyte Concentrate)Calcium Acetate (440 mg) + Sodium gluconate (1.09 g) + Magnesium acetate (860 mg) + Potassium acetate (690 mg) + Potassium Chloride (2.46 g) + Sodium acetate (2.72 g)LiquidIntravenousB. Braun Medical Inc.1998-09-04Not applicableCanada
LypholyteCalcium Acetate (440 mg) + Sodium gluconate (1.1 g) + Magnesium acetate (860 mg) + Potassium acetate (690 mg) + Potassium Chloride (2.5 g) + Sodium acetate (2.7 g)SolutionIntravenousPartners Health Care, Inc.1996-08-142008-01-10Canada
Lypholyte Multi-electrolyte Conc InjCalcium Acetate (22 mg) + Sodium gluconate (55 mg) + Magnesium acetate (43 mg) + Potassium acetate (34.5 mg) + Potassium Chloride (125 mg) + Sodium acetate (135 mg)LiquidIntravenousLyphomed, Division Of Fujisawa Canada Inc.1991-12-311996-09-10Canada
NutrilyteCalcium Acetate (22 mg/mL) + Sodium gluconate (55 mg/mL) + Magnesium acetate (43 mg/mL) + Potassium acetate (34.5 mg/mL) + Potassium Chloride (125 mg/mL) + Sodium acetate (135 mg/mL)Injection, solution, concentrateIntravenousAmerican Regent1990-09-30Not applicableUs
Zo Medical Zo Post Procedure Recovery SystemCalcium acetate monohydrate + Aluminum sulfate tetradecahydrate + Colloidal oatmealKitZo Skin Health Inc2014-11-14Not applicableUs
Categories
UNII
Y882YXF34X
CAS number
62-54-4
Weight
Average: 158.166
Monoisotopic: 157.989199835
Chemical Formula
C4H6CaO4
InChI Key
VSGNNIFQASZAOI-UHFFFAOYSA-L
InChI
InChI=1S/2C2H4O2.Ca/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2
IUPAC Name
calcium diacetate
SMILES
[Ca++].CC([O-])=O.CC([O-])=O

Pharmacology

Indication

Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.

Structured Indications
Pharmacodynamics

Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.

Mechanism of action

Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.

TargetActionsOrganism
APhosphate
binder
Human
Absorption

40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Calcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.

Half life
Not Available
Clearance
Not Available
Toxicity

Oral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinCalcium Acetate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinCalcium Acetate may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium Acetate.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Acetate.Approved
AmrinoneThe therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium Acetate.Approved
AzelnidipineThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
AzimilideThe therapeutic efficacy of Azimilide can be decreased when used in combination with Calcium Acetate.Investigational
BarnidipineThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium Acetate.Approved
BencyclaneThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium Acetate.Experimental
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
BenidipineThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Acetate.Approved, Withdrawn
CalcidiolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Calcipotriol.Approved
Calcium CarbonateThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Calcium Acetate.Approved
Calcium ChlorideThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Calcium Acetate.Approved
Calcium CitrateThe risk or severity of adverse effects can be increased when Calcium Citrate is combined with Calcium Acetate.Approved
Calcium glubionateThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Calcium Acetate.Approved
Calcium GluceptateThe risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Calcium Acetate.Approved
Calcium gluconateThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Calcium Acetate.Approved, Vet Approved
Calcium lactateThe risk or severity of adverse effects can be increased when Calcium lactate is combined with Calcium Acetate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe risk or severity of adverse effects can be increased when Calcium lactate gluconate is combined with Calcium Acetate.Experimental
Calcium laevulateThe risk or severity of adverse effects can be increased when Calcium laevulate is combined with Calcium Acetate.Experimental
Calcium pangamateThe risk or severity of adverse effects can be increased when Calcium pangamate is combined with Calcium Acetate.Experimental
Calcium PhosphateThe risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Calcium Acetate.Approved
CarboxyamidotriazoleThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium Acetate.Investigational
CaroverineThe therapeutic efficacy of Caroverine can be decreased when used in combination with Calcium Acetate.Experimental
CaseinThe risk or severity of adverse effects can be increased when Casein is combined with Calcium Acetate.Approved
CeftriaxoneThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Ceftriaxone.Approved
ChlorothiazideChlorothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved, Vet Approved
ChlortetracyclineThe serum concentration of Chlortetracycline can be decreased when it is combined with Calcium Acetate.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
CilnidipineThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
CinnarizineThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
CinoxacinCalcium Acetate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
ClevidipineThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Acetate.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Calcium Acetate.Approved, Investigational, Vet Approved
CyclopenthiazideCyclopenthiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Experimental
CymarinCalcium Acetate may increase the arrhythmogenic activities of Cymarin.Experimental
DarodipineThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Acetate.Experimental
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Calcium Acetate.Approved
DemeclocyclineThe serum concentration of Demeclocycline can be decreased when it is combined with Calcium Acetate.Approved
DeslanosideCalcium Acetate may increase the arrhythmogenic activities of Deslanoside.Approved
DigitoxinCalcium Acetate may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinCalcium Acetate may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Calcium Acetate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrotachysterolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Dihydrotachysterol.Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Calcium Acetate.Approved
Dipotassium phosphateCalcium Acetate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DobutamineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Acetate.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium Acetate.Approved
DotarizineThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium Acetate.Investigational
DoxercalciferolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Doxercalciferol.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Calcium Acetate.Approved, Investigational, Vet Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Calcium Acetate.Approved
EnoxacinCalcium Acetate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EperisoneThe therapeutic efficacy of Eperisone can be decreased when used in combination with Calcium Acetate.Approved, Investigational
ErgocalciferolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Ergocalciferol.Approved, Nutraceutical
EstramustineCalcium Acetate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Calcium Acetate.Approved
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
FendilineThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium Acetate.Withdrawn
FleroxacinCalcium Acetate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlumequineCalcium Acetate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlunarizineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium Acetate.Approved
GabapentinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium Acetate.Approved, Investigational
GallopamilThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium Acetate.Investigational
GarenoxacinCalcium Acetate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinCalcium Acetate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemifloxacinCalcium Acetate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GitoformateCalcium Acetate may increase the arrhythmogenic activities of Gitoformate.Experimental
GrepafloxacinCalcium Acetate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational, Withdrawn
HydrochlorothiazideHydrochlorothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved, Investigational
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Acetate.Approved, Investigational
IndapamideIndapamide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium Acetate.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
LamotrigineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Lanatoside CCalcium Acetate may increase the arrhythmogenic activities of Lanatoside C.Experimental
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
LevofloxacinCalcium Acetate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium Acetate.Approved
LidoflazineThe therapeutic efficacy of Lidoflazine can be decreased when used in combination with Calcium Acetate.Experimental
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium Acetate.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Calcium Acetate.Approved
Lipoic AcidCalcium Acetate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
Magnesium SulfateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium Acetate.Approved, Vet Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
MethyclothiazideMethyclothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
MetildigoxinCalcium Acetate may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetolazoneMetolazone may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Calcium Acetate.Investigational, Withdrawn
MinocyclineThe serum concentration of Minocycline can be decreased when it is combined with Calcium Acetate.Approved, Investigational
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Acetate.Investigational
Nalidixic AcidCalcium Acetate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NemonoxacinCalcium Acetate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Acetate.Approved
NifedipineThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Acetate.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Acetate.Experimental
NiludipineThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium Acetate.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
NimesulideThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Acetate.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Acetate.Approved
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Acetate.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
NorfloxacinCalcium Acetate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OleandrinCalcium Acetate may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Calcium Acetate.Experimental, Investigational
OuabainCalcium Acetate may increase the arrhythmogenic activities of Ouabain.Approved
Oxolinic acidCalcium Acetate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium Acetate.Approved
ParicalcitolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Paricalcitol.Approved, Investigational
PazufloxacinCalcium Acetate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinCalcium Acetate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PerhexilineThe therapeutic efficacy of Perhexiline can be decreased when used in combination with Calcium Acetate.Approved, Investigational
PeruvosideCalcium Acetate may increase the arrhythmogenic activities of Peruvoside.Experimental
PinaveriumThe therapeutic efficacy of Pinaverium can be decreased when used in combination with Calcium Acetate.Approved
Pipemidic acidCalcium Acetate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidCalcium Acetate can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PolythiazidePolythiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
PregabalinThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Calcium Acetate.Approved, Illicit, Investigational
PrenylamineThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium Acetate.Withdrawn
ProscillaridinCalcium Acetate may increase the arrhythmogenic activities of Proscillaridin.Experimental
PrulifloxacinCalcium Acetate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
QuinethazoneQuinethazone may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Calcium Acetate.Approved, Investigational
RosoxacinCalcium Acetate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RufloxacinCalcium Acetate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SitafloxacinCalcium Acetate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateCalcium Acetate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateCalcium Acetate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinCalcium Acetate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Calcium Acetate.Approved
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Calcium Acetate.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Calcium Acetate.Approved
TemafloxacinCalcium Acetate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TerodilineThe therapeutic efficacy of Terodiline can be decreased when used in combination with Calcium Acetate.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Acetate.Investigational
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Calcium Acetate.Approved
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Calcium Acetate.Approved, Investigational, Vet Approved
Tolfenamic AcidThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Acetate.Approved
TranilastThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Acetate.Approved, Investigational
TrichlormethiazideTrichlormethiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved, Vet Approved
TriethylenetetramineThe serum concentration of Triethylenetetramine can be decreased when it is combined with Calcium Acetate.Approved
TrovafloxacinCalcium Acetate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
VerapamilThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Acetate.Approved
VinpocetineThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium Acetate.Investigational
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium Acetate.Approved
ZiconotideThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Acetate.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Calcium Acetate.Approved
Food Interactions
Not Available

References

Synthesis Reference

Alan B. Gancy, "Process of making calcium acetate deicing agents and product." U.S. Patent US4444672, issued November, 1946.

US4444672
General References
Not Available
External Links
KEGG Drug
D00931
PubChem Compound
6116
PubChem Substance
46507985
ChemSpider
5890
ChEBI
3310
ChEMBL
CHEMBL1200800
PharmGKB
PA164746897
Drugs.com
Drugs.com Drug Page
Wikipedia
Calcium_Acetate
ATC Codes
A11GB01 — Ascorbic acid (vit c) and calciumV03AE04 — Calcium acetate and magnesium carbonateV03AE07 — Calcium acetate
AHFS Codes
  • 88:29.00* — Minerals
  • 40:18.19 — Phosphate-removing Agents
FDA label
Download (25.6 KB)
MSDS
Download (72.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceChronic Kidney Disease (CKD) / Healthy Volunteers / Test Ferric Hydroxide Adipate as Phosphate Binder in Healthy Subjects1
3CompletedPreventionHyperphosphataemia / Renal Failure1
3CompletedTreatmentChronic Kidney Disease (CKD) / Peritoneal dialysis therapy1
3CompletedTreatmentHyperphosphataemia / Renal Failure1
3Not Yet RecruitingTreatmentHyperphosphataemia1
3RecruitingTreatmentHyperphosphataemia1
3Unknown StatusTreatmentChronic Kidney Disease (CKD)1
4CompletedPreventionWe Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients1
4CompletedTreatmentArteriosclerosis / Calcinosis / Hyperparathyroidism, Secondary1
4CompletedTreatmentCardiovascular Events / Hemodialysis-dependent patients / Hyperphosphataemia1
4CompletedTreatmentChronic Kidney Disease (CKD)1
4TerminatedPreventionChronic Kidney Disease (CKD)1
Not AvailableCompletedPreventionChronic Kidney Disease (CKD)1
Not AvailableCompletedPreventionRenal Failure1
Not AvailableUnknown StatusTreatmentHaemodialyzed Patients / Hyperphosphataemia1

Pharmacoeconomics

Manufacturers
  • Roxane laboratories inc
  • Fresenius medical care north america
  • Cypress pharmaceutical inc
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionTopical
CapsuleOral667 mg/1
TabletOral667 mg/1
TabletOral667 mg
SolutionIntravenous
LiquidIntravenous
Injection, solution, concentrateIntravenous
SolutionOral667 mg/5mL
Kit
Prices
Unit descriptionCostUnit
PhosLo 667 mg capsule1.05USD capsule
Phoslo 667 mg tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6576665No2001-04-032021-04-03Us
US6875445No2001-07-302021-07-30Us
US8591938No2010-02-232030-02-23Us
US8592480No2007-07-202027-07-20Us
US9089528No2007-07-202027-07-20Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)> 160 °CNot Available
Predicted Properties
PropertyValueSource
Water Solubility147.0 mg/mLALOGPS
logP0.24ALOGPS
logP-0.22ChemAxon
logS-0.03ALOGPS
pKa (Strongest Acidic)4.54ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.13 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity23.48 m3·mol-1ChemAxon
Polarizability4.96 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.705
Blood Brain Barrier+0.9601
Caco-2 permeable-0.5258
P-glycoprotein substrateNon-substrate0.8366
P-glycoprotein inhibitor INon-inhibitor0.9806
P-glycoprotein inhibitor IINon-inhibitor0.9866
Renal organic cation transporterNon-inhibitor0.9609
CYP450 2C9 substrateNon-substrate0.8335
CYP450 2D6 substrateNon-substrate0.9164
CYP450 3A4 substrateNon-substrate0.7384
CYP450 1A2 substrateNon-inhibitor0.9381
CYP450 2C9 inhibitorNon-inhibitor0.9273
CYP450 2D6 inhibitorNon-inhibitor0.9462
CYP450 2C19 inhibitorNon-inhibitor0.9608
CYP450 3A4 inhibitorNon-inhibitor0.9627
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.985
Ames testNon AMES toxic0.9042
CarcinogenicityCarcinogens 0.5617
BiodegradationReady biodegradable0.9734
Rat acute toxicity1.8756 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9812
hERG inhibition (predictor II)Non-inhibitor0.9888
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as carboxylic acids. These are compounds containing a carboxylic acid group with the formula -C(=O)OH.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Carboxylic acids
Direct Parent
Carboxylic acids
Alternative Parents
Monocarboxylic acids and derivatives / Organic salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Monocarboxylic acid or derivatives / Carboxylic acid / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic salt / Organooxygen compound / Carbonyl group / Aliphatic acyclic compound
Molecular Framework
Not Available
External Descriptors
calcium salt (CHEBI:3310)

Targets

Kind
Small molecule
Organism
Human
Pharmacological action
Yes
Actions
Binder
References
  1. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. 1989 Oct;36(4):690-5. [PubMed:2811066]
  2. Nolan CR, Qunibi WY: Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Curr Opin Nephrol Hypertens. 2003 Jul;12(4):373-9. [PubMed:12815333]
  3. Nolan CR, Qunibi WY: Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney Int Suppl. 2005 Jun;(95):S13-20. [PubMed:15882308]
  4. Nolan CR: Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines. Kidney Int Suppl. 2005 Jul;(96):S7-14. [PubMed:15954948]

Drug created on June 13, 2005 07:24 / Updated on November 22, 2017 12:26